The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Open accessAbstract
OBJECTIVE: To synthesize updated evidence on the cost-effectiveness (CE) of interventions to manage diabetes, its complications, and comorbidities. RESEARCH DESIGN AND METHODS: We conducted a systematic literature review of studies from high-income countries evaluating the CE of diabetes management interventions recommended by the American Diabetes Association (ADA) and published in English between June 2008 and July 2017. We also incorporated studies from a previous CE review from the period 1985–2008. We classified the interventions based on their strength of evidence (strong, supportive, or uncertain) and levels of CE: cost-saving (more health benefit at a lower cost), very cost-effective (≤$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001–$50,000 per LYG or QALY), marginally cost-effective ($50,001–$100,000 per LYG or QALY), or not cost-effective (>$100,000 per LYG or QALY). Costs were measured in 2017 U.S. dollars. RESULTS: Seventy-three new studies met our inclusion criteria. These were combined with 49 studies from the previous review to yield 122 studies over the period 1985–2017. A large majority of the ADA-recommended interventions remain cost-effective. Specifically, we found strong evidence that the following ADA-recommended interventions are cost-saving or very cost-effective: In the cost-saving category are 1) ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy for intensive hypertension management compared with standard hypertension management, 2) ACEI/ARB therapy to prevent chronic kidney disease and/or end-stage renal disease in people with albuminuria compared with no ACEI/ARB therapy, 3) comprehensive foot care and patient education to prevent and treat foot ulcers among those at moderate/high risk of developing foot ulcers, 4) telemedicine for diabetic retinopathy screening compared with office screening, and 5) bariatric surgery compared with no surgery for individuals with type 2 diabetes (T2D) and obesity (BMI ≥30 kg/m2). In the very cost-effective category are 1) intensive glycemic management (targeting A1C <7%) compared with conventional glycemic management (targeting an A1C level of 8–10%) for individuals with newly diagnosed T2D, 2) multicomponent interventions (involving behavior change/education and pharmacological therapy targeting hyperglycemia, hypertension, dyslipidemia, microalbuminuria, nephropathy/retinopathy, secondary prevention of cardiovascular disease with aspirin) compared with usual care, 3) statin therapy compared with no statin therapy for individuals with T2D and history of cardiovascular disease, 4) diabetes self-management education and support compared with usual care, 5) T2D screening every 3 years starting at age 45 years compared with no screening, 6) integrated, patient-centered care compared with usual care, 7) smoking cessation compared with no smoking cessation, 8) daily aspirin use as primary prevention for cardiovascular complications compared with usual care, 9) self-monitoring of blood glucose three times per day compared with once per day among those using insulin, 10) intensive glycemic management compared with conventional insulin therapy for T2D among adults aged ≥50 years, and 11) collaborative care for depression compared with usual care. CONCLUSIONS: Complementing professional treatment recommendations, our systematic review provides an updated understanding of the potential value of interventions to manage diabetes and its complications and can assist clinicians and payers in prioritizing interventions and health care resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Effects of aspirin for primary prevention in persons with diabetes mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804988 · Cited by 1,200
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979
Self-citationLaiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers
American Diabetes Association (2019) · Clinical Diabetes · doi:10.2337/cd18-0105 · Cited by 539
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
Self-citationGupta, J. K., Daniels, J. P., Middleton, L. J., Pattison, H. M., Prileszky, G., Roberts, T. E., Sanghera, S., Barton, P., Gray, R., Kai, J., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19880 · Cited by 399
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62162-0 · Cited by 287
Self-citation
Cited by
Human Wound and Its Burden: Updated 2020 Compendium of Estimates
Sen, C. K. (2021) · Advances in Wound Care · doi:10.1089/wound.2021.0026 · Cited by 1,017
Introduction: Standards of Medical Care in Diabetes—2022
American Diabetes Association (2022) · Diabetes Care · doi:10.2337/dc22-sint · Cited by 807
The Recent Progress and Applications of Digital Technologies in Healthcare: A Review
Senbekov, M., Saliev, T., Bukeyeva, Z., Almabayeva, A., Zhanaliyeva, M., Aitenova, N., Toishibekov, Y., & Fakhradiyev, I. (2020) · International Journal of Telemedicine and Applications · doi:10.1155/2020/8830200 · Cited by 415
Human Wound and Its Burden: Updated 2022 Compendium of Estimates
Sen, C. K. (2023) · Advances in Wound Care · doi:10.1089/wound.2023.0150 · Cited by 360
Diabetic foot ulcers: Classification, risk factors and management
Wang, X., Yuan, C.-X., Xu, B., & Yu, Z. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1049 · Cited by 305
Introduction: Standards of Medical Care in Diabetes—2021
(2021) · Diabetes Care · doi:10.2337/dc21-sint · Cited by 265
Lin, S., Ma, Y., Xu, Y., Lu, L., He, J., Zhu, J., Peng, Y., Yu, T., Congdon, N., & Zou, H. (2023) · JMIR Public Health and Surveillance · doi:10.2196/41624 · Cited by 52
Yang, C.-Y., Chen, Y.-R., Ou, H.-T., & Kuo, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01211-4 · Cited by 51
Betzler, B. K., Chee, E. Y. L., He, F., Lim, C. C., Ho, J., Hamzah, H., Tan, N. C., Liew, G., McKay, G. J., Hogg, R. E., et al. (2023) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocad179 · Cited by 42
Davidson, P., LaManna, J., Davis, J., Ojeda, M. M., Hyer, S., Dickinson, J. K., Todd, A., Hammons, T. M., Mohammed Fahim, S., McDaniel, C. C., et al. (2022) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106211070266 · Cited by 32
Metadata
- Authors
- Siegel, K. R., Ali, M. K., Zhou, X., Ng, B. P., Jawanda, S., Proia, K., Zhang, X., Gregg, E. W., Albright, A. L., & Zhang, P.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-06-11
- Volume
- 43
- Issue
- 7
- Pages
- 1557-1592
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3036236993
- Cited by
- 164
- References
- 18
- FWCI
- 20.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.